• Clinical Evidence

Evaluation of the Use of Sitagliptin for Insulin Resistance in Burn Patients

Setting: Largest (425-bed) U.S. military hospital, academic medical center and Level 1 trauma center.

Objective

This retrospective review compares exogenous insulin requirements before and after sitagliptin initiation as well as time to liberation from intravenous insulin infusion (managed with EndoTool) for patients admitted to a burn intensive care unit.

Setting

Largest (425-bed) U.S. military hospital, academic medical center and Level 1 trauma center.

Results

  • Median exogenous insulin requirements decreased 68.2% after sitagliptin initiation, from 114.3 to 36.3 units/day.
  • Incidence of hyperglycemia >180 mg/dL decreased 15% after sitagliptin initiation, from 90.9% to 77.3% of patients.
  • Incidence of hypoglycemia <70 mg/dL decreased 33% after sitagliptin initiation, from 13.6% to 9.1% of patients.
  • Median time to liberation from intravenous insulin infusion was 3 days after sitagliptin initiation.

Conclusions

The addition of sitagliptin as an adjunct anti-hyperglycemic agent following burn injury is associated with a reduction in exogenous insulin requirements as well as a reduction in episodes of hyperglycemia and hypoglycemia, and allows liberation from intravenous insulin infusion (managed with EndoTool) over a 3-day period.

Objective

This retrospective review compares exogenous insulin requirements before and after sitagliptin initiation as well as time to liberation from intravenous insulin infusion (managed with EndoTool) for patients admitted to a burn intensive care unit.

Setting

Largest (425-bed) U.S. military hospital, academic medical center and Level 1 trauma center.

Results
  • Median exogenous insulin requirements decreased 68.2% after sitagliptin initiation, from 114.3 to 36.3 units/day.
  • Incidence of hyperglycemia >180 mg/dL decreased 15% after sitagliptin initiation, from 90.9% to 77.3% of patients.
  • Incidence of hypoglycemia <70 mg/dL decreased 33% after sitagliptin initiation, from 13.6% to 9.1% of patients.
  • Median time to liberation from intravenous insulin infusion was 3 days after sitagliptin initiation.
Conclusions

The addition of sitagliptin as an adjunct anti-hyperglycemic agent following burn injury is associated with a reduction in exogenous insulin requirements as well as a reduction in episodes of hyperglycemia and hypoglycemia, and allows liberation from intravenous insulin infusion (managed with EndoTool) over a 3-day period.

References

Authors

Kaitlin Pruskowski; Beth Shield; Craig Ainsworth; Leopoldo Cancio.

Source

Published in International Journal of Burns and Trauma, Volume 10, Issue5, p237-245.

Year

2020

Quick navigation
Objective
Setting
Results
Conclusions
References

Objective

This retrospective review compares exogenous insulin requirements before and after sitagliptin initiation as well as time to liberation from intravenous insulin infusion (managed with EndoTool) for patients admitted to a burn intensive care unit.

Setting

Largest (425-bed) U.S. military hospital, academic medical center and Level 1 trauma center.

Results
  • Median exogenous insulin requirements decreased 68.2% after sitagliptin initiation, from 114.3 to 36.3 units/day.
  • Incidence of hyperglycemia >180 mg/dL decreased 15% after sitagliptin initiation, from 90.9% to 77.3% of patients.
  • Incidence of hypoglycemia <70 mg/dL decreased 33% after sitagliptin initiation, from 13.6% to 9.1% of patients.
  • Median time to liberation from intravenous insulin infusion was 3 days after sitagliptin initiation.
Conclusions

The addition of sitagliptin as an adjunct anti-hyperglycemic agent following burn injury is associated with a reduction in exogenous insulin requirements as well as a reduction in episodes of hyperglycemia and hypoglycemia, and allows liberation from intravenous insulin infusion (managed with EndoTool) over a 3-day period.

References

Authors

Kaitlin Pruskowski; Beth Shield; Craig Ainsworth; Leopoldo Cancio.

Source

Published in International Journal of Burns and Trauma, Volume 10, Issue5, p237-245.

Year

2020

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

The objective of this study was to evaluate the impact of renal insufficiency on hypoglycemia rates in patients treated for Diabetic Ketoacidosis (DKA) utilizing a computerized insulin dosing algorithm.
Image
  • Clinical Evidence

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

20 minute read

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

The objective of this study was to evaluate the impact of different blood glucose (BG) target ranges for IV insulin infusions on inpatient glucose metrics, specifically focusing on hypo and hyperglycemic events, duration of IV insulin therapy, and length of stay (LOS) in the hospital.
Image
  • Clinical Evidence

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

To compare the effectiveness of EndoTool IV in reducing hospital LOS and hypoglycemia rates compared to standard insulin infusion protocols.
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.